PriceTargets.com logo

Lumos Pharma - LUMO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 172.11 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$8.82 As of 08/18/2022 03:02 PM ET
▲ +0.12 (1.38%)

This chart shows the closing price for LUMO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lumos Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LUMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LUMO

Analyst Price Target is $24.00
▲ +172.11% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lumos Pharma in the last 3 months. The average price target is $24.00, with a high forecast of $28.00 and a low forecast of $20.00. The average price target represents a 172.11% upside from the last price of $8.82.

This chart shows the closing price for LUMO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Lumos Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/20/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/19/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022Roth CapitalReiterated RatingBuyLow
7/19/2022OppenheimerInitiated CoverageOutperform$20.00Low
11/4/2021HC WainwrightBoost TargetBuy$27.00 ➝ $28.00Medium
8/6/2021JonestradingReiterated RatingBuy$25.00Low
7/22/2021Roth CapitalLower TargetBuy$51.00 ➝ $35.00High
7/21/2021HC WainwrightLower TargetBuy$34.00 ➝ $27.00High
4/13/2021JonestradingInitiated CoverageBuy$34.00High
3/11/2021Stifel NicolausUpgradeHold ➝ Buy$4.00 ➝ $24.00High
12/2/2020Cantor FitzgeraldInitiated CoverageOverweight$32.00Medium
11/23/2020HC WainwrightBoost TargetBuy$33.00 ➝ $34.00High
8/25/2020Piper SandlerInitiated CoverageOverweight$26.00Medium
8/17/2020Roth CapitalReiterated RatingBuy$51.00High
8/4/2020HC WainwrightInitiated CoverageBuyLow
5/1/2020Roth CapitalInitiated CoverageBuyHigh
4/16/2020Jefferies Financial GroupInitiated CoverageBuy$12.00Low
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/20/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/19/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/19/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/18/2022

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Lumos Pharma logo
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Read More

Today's Range

Now: $8.82
Low: $8.80
High: $8.82

50 Day Range

MA: $7.72
Low: $6.68
High: $8.85

52 Week Range

Now: $8.82
Low: $6.15
High: $11.52

Volume

200 shs

Average Volume

13,378 shs

Market Capitalization

$73.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Lumos Pharma?

The following Wall Street analysts have issued research reports on Lumos Pharma in the last twelve months: HC Wainwright, Oppenheimer Holdings Inc., and Roth Capital.
View the latest analyst ratings for LUMO.

What is the current price target for Lumos Pharma?

2 Wall Street analysts have set twelve-month price targets for Lumos Pharma in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 175.9%. HC Wainwright has the highest price target set, predicting LUMO will reach $28.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $20.00 for Lumos Pharma in the next year.
View the latest price targets for LUMO.

What is the current consensus analyst rating for Lumos Pharma?

Lumos Pharma currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LUMO will outperform the market and that investors should add to their positions of Lumos Pharma.
View the latest ratings for LUMO.

What other companies compete with Lumos Pharma?

Other companies that are similar to Lumos Pharma include Medicenna Therapeutics, Oncolytics Biotech, Synlogic, Palatin Technologies and MEI Pharma. Learn More about companies similar to Lumos Pharma.

How do I contact Lumos Pharma's investor relations team?

Lumos Pharma's physical mailing address is 4200 MARATHON BLVD. SUITE 200, AUSTIN TX, 78756. The company's listed phone number is (512) 215-2630 and its investor relations email address is [email protected] The official website for Lumos Pharma is www.lumos-pharma.com. Learn More about contacing Lumos Pharma investor relations.